Analyst Report: Medtech Startups to Watch from LSI USA ‘26

LSI USA ’26 has wrapped, but the real work starts now. Each year, our team reviews hundreds of presenting companies to identify a select group that stands out across technology, recent milestones, and market opportunity. From this year’s cohort of more than 400 innovators, five medtech startups emerged as particularly compelling based on their recent progress and the markets they are targeting.

Selecting just five was no easy task. The depth of innovation across the event continues to rise, making differentiation increasingly difficult. Still, a closer look at the underlying data reveals why these companies earned a closer examination.

Five Standout Medtech Startups to Watch

Lady Technologies

Lady Technologies is tackling fertility tracking with a differentiated technical approach through its kegg device. Unlike traditional solutions that depend on hormone testing or temperature tracking, kegg measures changes in cervical fluid electrolyte composition using impedance spectroscopy. This enables users to identify shifts in fertility earlier and with greater precision.

This distinction matters. Cervical mucus plays a critical role in reproductive success, acting as both a barrier and a facilitator depending on its composition. By detecting these changes in advance, users can better plan or prevent pregnancy over a wider time horizon.

The broader market continues to expand. Approximately 12% of women in the U.S. between the ages of 15 and 44 have difficulty conceiving or sustaining a pregnancy, according to CDC data. Ovulatory dysfunction remains a leading cause, reinforcing the value of tools that improve timing accuracy.

​​From a commercial standpoint, kegg’s one-time purchase model also sets it apart. Many competing solutions rely on recurring purchases or subscription fees, which can create friction for long-term use.

Revitalise

Revitalise is focused on improving precision in ophthalmic surgery through a soft robotic system designed for retinal procedures. Its platform combines flexible instrumentation with AI-assisted stabilization and haptic feedback, allowing surgeons to navigate delicate structures within the eye more effectively.

Current tools are largely rigid, limiting maneuverability in the posterior segment of the eye. This becomes a growing constraint as new therapies, including gene and cell-based treatments, require increasingly precise delivery methods.

The opportunity is significant. Each year, roughly 225,000 vitrectomies are performed in the U.S., alongside more than 3.4 million intravitreal injections within the Medicare population alone. As the prevalence of retinal diseases rises with aging populations, demand for advanced surgical capabilities is expected to follow.

Revitalise is positioning its system as a foundational platform for these emerging therapies, rather than a simple upgrade to existing tools.

Able Innovations

Able Innovations is bringing robotics into hospital workflows with its ALTA Platform, which enables a single caregiver to perform lateral patient transfers without manual lifting. This directly addresses one of the most physically demanding and injury-prone tasks in healthcare settings.

Existing solutions often require multiple staff members and still expose both patients and caregivers to risk. By combining sensors, AI-driven analytics, and soft robotics, the ALTA system reduces the need for physical exertion while improving consistency.

The scale of the problem is substantial. Healthcare workers have the highest rates of musculoskeletal injury of any occupational group (more than mining, construction, and manufacturing), and patient transfers are a major contributor. These movements occur billions of times annually, with associated costs exceeding $20 billion each year in Canada alone.

In the U.S., workforce shortages and increasing patient demand are intensifying the need for automation in non-clinical tasks, making this an area of growing focus.

Channel Robotics

Channel Robotics is taking a different approach to surgical robotics by developing a handheld system that integrates directly with existing endoscopes. Its platform pairs a controller with a single-use instrument to deliver AI-assisted precision within the visual field of the scope.

This model avoids the need for large capital installations, which have traditionally limited the adoption of robotic systems. By enabling advanced capabilities without requiring new infrastructure, the company is targeting settings such as ambulatory surgery centers where cost constraints are more pronounced.

Flexible endoscopy is already one of the highest-volume procedural areas in medicine. In the U.S. alone, more than 17 million GI endoscopy procedures are performed each year. As procedures become more complex, the need for enhanced control and dexterity continues to increase.

StimAire

StimAire is rethinking treatment for obstructive sleep apnea with a battery-free, injectable neurostimulation device. Unlike existing systems that require multi-hour surgeries, this approach is delivered in a short office-based procedure under local anesthesia.

The device is extremely small and is activated wirelessly through a wearable component used during sleep. Patients can begin therapy immediately following the procedure.

The market opportunity is already well established. Inspire Medical Systems has demonstrated strong demand for neurostimulation-based therapies, reporting approximately $912 million in revenue in 2025. However, its surgical approach creates barriers to broader adoption.

With more than one billion people affected by sleep apnea globally, a lower-cost and less invasive alternative has the potential to significantly expand the treated population.

Looking ahead

These five medtech startups represent just a small slice of the innovation showcased at LSI USA ’26. As we continue to analyze presentations and data from the event, more insights will emerge, but this group offers a clear snapshot of where the industry is heading.